Eli Lilly and Company Reports Solid Start to the Year With First-Quarter 2012 Results, Raises EPS Guidance

INDIANAPOLIS, April 25, 2012 /PRNewswire/ --Worldwide revenue declined 4 percent in the first quarter of 2012, driven by Zyprexa patent expirations, partially offset by significant growth in other pro…
Read the full story: BioSpace.com Featured News